104 related articles for article (PubMed ID: 20887721)
21. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
22. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
Li JG; Chen C; Liu-Chen LY
Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303
[TBL] [Abstract][Full Text] [Related]
23. G(z) can mediate the acute actions of mu- and kappa-opioids but is not involved in opioid-induced adenylyl cyclase supersensitization.
Tso PH; Wong YH
J Pharmacol Exp Ther; 2000 Oct; 295(1):168-76. PubMed ID: 10991975
[TBL] [Abstract][Full Text] [Related]
24. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
25. Functional coupling of a mu opioid receptor to G proteins and adenylyl cyclase: modulation by chronic morphine treatment.
Chen Y; Liu J; Yu L
Addict Biol; 1996; 1(1):49-59. PubMed ID: 12893486
[TBL] [Abstract][Full Text] [Related]
26. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
27. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
28. Analysis of binding domain and function of chimeric mu/kappa opioid receptors to ohmefentanyl stereoisomers.
Feng YP; Chen LW; Zhou DH; Chen J; Xu XJ; Chi ZQ
Acta Pharmacol Sin; 2001 Nov; 22(11):981-5. PubMed ID: 11749787
[TBL] [Abstract][Full Text] [Related]
29. Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause dependence.
Wang YH; Sun JF; Tao YM; Xu XJ; Chi ZQ; Liu JG
Acta Pharmacol Sin; 2010 Apr; 31(4):393-8. PubMed ID: 20228826
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
31. Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor.
Harrison C; Rowbotham DJ; Grandy DK; Lambert DG
Br J Pharmacol; 2000 Nov; 131(6):1220-6. PubMed ID: 11082131
[TBL] [Abstract][Full Text] [Related]
32. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2.
Monory K; Bourin MC; Spetea M; Tömböly C; Tóth G; Matthes HW; Kieffer BL; Hanoune J; Borsodi A
Eur J Neurosci; 2000 Feb; 12(2):577-84. PubMed ID: 10712637
[TBL] [Abstract][Full Text] [Related]
33. Salvinorin A: allosteric interactions at the mu-opioid receptor.
Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
[TBL] [Abstract][Full Text] [Related]
34. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.
Brasel CM; Sawyer GW; Stevens CW
Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720
[TBL] [Abstract][Full Text] [Related]
35. Third intracellular loop of glucagon like-peptide-1 receptor is coupled with endogenous mono-ADP-ribosyltransferase - novel type of receptor regulation?
Deželak M; Bavec A
Eur J Pharmacol; 2011 Sep; 666(1-3):35-42. PubMed ID: 21635883
[TBL] [Abstract][Full Text] [Related]
36. A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells.
Knapman A; Abogadie F; McIntrye P; Connor M
J Biomol Screen; 2014 Feb; 19(2):223-31. PubMed ID: 23989451
[TBL] [Abstract][Full Text] [Related]
37. Effect of electromagnetic field on cyclic adenosine monophosphate (cAMP) in a human mu-opioid receptor cell model.
Ross CL; Teli T; Harrison BS
Electromagn Biol Med; 2016; 35(3):206-13. PubMed ID: 26151161
[TBL] [Abstract][Full Text] [Related]
38. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.
Talbot JN; Roman DL; Clark MJ; Roof RA; Tesmer JJ; Neubig RR; Traynor JR
J Neurochem; 2010 Feb; 112(4):1026-34. PubMed ID: 20002516
[TBL] [Abstract][Full Text] [Related]
39. Expression of EGFP-amino-tagged human mu opioid receptor in Drosophila Schneider 2 cells: a potential expression system for large-scale production of G-protein coupled receptors.
Perret BG; Wagner R; Lecat S; Brillet K; Rabut G; Bucher B; Pattus F
Protein Expr Purif; 2003 Sep; 31(1):123-32. PubMed ID: 12963349
[TBL] [Abstract][Full Text] [Related]
40. Comparative modeling of human kappa opioid receptor and docking analysis with the peptide YFa.
Patra MC; Kumar K; Pasha S; Chopra M
J Mol Graph Model; 2012 Mar; 33():44-51. PubMed ID: 22172315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
